Overall survival: 1 st line therapy
|
|
- Stella Fleming
- 5 years ago
- Views:
Transcription
1 1
2
3 3
4 Overall survival: 1 st line therapy
5 2-year OS phase III studies mm Prices per month of oncology medicin Bloomberg Business weekly 26 Feb 2015
6 Presented By Veena Shankaran at 2016 ASCO Annual Meeting Presented By Veena Shankaran at 2016 ASCO Annual Meeting
7
8
9
10 30 countries, leading national melanoma centers 30 countries filled the survey 35 oncology Sweden center included 500 Russian Federation 4000 Belgium 350 Poland 1000 Belarus 250 Slovenia 150 Spain 400 Albania 30
11 Western Europe Eastern Europe and South Eastern Europe VEMURAFENIB DABRAFENIB VEMURAFENIB COBIMETINIB DABRAFENIB TRAMETINIB IPILIMUMAB PEMBROLIZUMAB NIVOLUMAB Austria Belgium ** ** Denmark France Germany Greece ** ** Italy Netherlands Portugal ** ** ** ** ** ** ** Spain *** *** Sweden Switzerland ** UK Albania Belarus Bosnia and Herzegovina Bulgaria Croatia Czech republic * * ** ** Estonia Hungary ** ** ** ** ** Lithuania Macedonia Montenegro ** Poland * * ** ** Romania Russia *** **** **** ** Serbia Slovenia Ukraine Registered Reimbursed Not registered Not reimbursed Switzerland: T-Vec registration and reimbursement *Reimbursed, but only for first-line treatment **Reimbursed, but with large and time-consuming administrative work needed to obtain the medicine for the patient ***Reimbursed, but not fully available due to the hospital-restricted budget ****Reimbursed, but not available due to the drug shortage
12 Country Estimated total number of metastatic melanoma patients Estimated % of patients treated with innovative medicines Estimated % of patients without access to innovative medicines Western Europe Austria 200 >90% 10%* / Belgium % 10%* / Denmark 350 >90% 10%* / France 2000 >90% 10%* / Germany 3000 >90% 10%* / Greece NA 70-90% 10%* / Italy % 10%* / Netherlands % 10%* / Portugal % 50% 100 Spain % 10%* / Sweden % 30%* / Switzerland % 10%* / UK % 10%* / Total WE Eastern and South-Eastern Europe Albania % 70% 21 Belarus 250 <10% 90% 225 Bosnia and 60 <10% 90% 54 Herzegovina Bulgaria % 50% 75 Croatia % 70% 70 Czech republic % 50% 200 Estonia % 30% 15 Hungary % 30% 120 Lithuania % 50% 25 Macedonia 80 <10% 90% 72 Montenegro % 70% 21 Poland % 10%* / Romania NA 10-30% 70% NA Russia 4000 <10% 90% 3600 Serbia 200 <10% 90% 180 Slovenia 150 >90% 10%* / Ukraine 500 <10% 90% 450 Total SEE Total WE+EE+SEE Estimated number of patients without access to innovative medicines patients with metastatic melanoma in Europe 7450 (39.7%) treated in Eastern and South-Eastern Europe 5128/7450 (69%) do not have the access to first-line therapy recommended by the European guidelines (ESMO, EDF/EORTC/EADO). 5228/19250 (27%), i.e. almost third of all metastatic melanoma patients do not have access to innovative medicines. *never in the first-line treatment
13 Serbia: vemurafenib reimbursed (without MEK inhibitor) pembrolizumab reimbursed for BRAF negative patients Croatia: dabrafenib trametinib reimbursed pembrolizumab reimbursed Romania: vemurafenib, dabrafenib trametinib nivolumab reimbursed Estonia: nivolumab, pembrolizumab reimbursed BRAF+MEK inhibitor reimbursed DELAY IN ACCESS THROUGH REIMBURSEMENT: 4-5 YEARS
14 Country Austria Belgium Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Malta Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden Switzerland United Kingdom nivo+ipi X X X X X X X X X X X X EMA registration: May 2016 Reimbursed in 32.4% countries
15 Difficulties in implementing CU and EAP programmes: unharmonised legislative in some countries programmes are active only until the EMA registration, while reimbursement is in significant delay Insufficient number of clinical studies At least one clinical study for stage IV melanoma was available in 12/13 (92%) Western centers, and 6/17 (35%) from Eastern Europe centers in the survey period.
16
17 Clinically meaningful benefit of the treatment Acceptable toxicity profile Improvement of quality of life 17
18 18
19 MCBS v1.1 19
20 20
21 Grading derived from the ESMO-MCBS provides a backbone for value evaluations for cancer medicines. ESMO-MCBS A+B for curative therapies and 4+5 for noncurative therapies should be highlighted for accelerated assessment of value and cost-effectiveness. While a high ESMO-MCBS score does not automatically imply high value (that depends on the price), the scale can be used to frame such considerations and can help public policymakers advance accountability for reasonableness in resource allocation deliberations 21
22 Presented By Elisabeth De Vries at 2017 ASCO Annual Meeting 22
23 1. ESMO in current and future guidelines 2. Doctors in everyday practice (patient care and teaching) 3. Academic groups 4. Industry 5. Organisations and countries using the scale as policy tool Presented By Elisabeth De Vries at 2017 ASCO Annual Meeting 23
24 24
25 1. ESMO in current and future guidelines 2. Doctors in everyday practice (patient care and teaching) 3. Academic groups 4. Industry 5. Organisations and countries using the scale as policy tool Presented By Elisabeth De Vries at 2017 ASCO Annual Meeting 25
26 Western Europe Eastern Europe and South Eastern Europe VEMURAFENIB DABRAFENIB VEMURAFENIB COBIMETINIB DABRAFENIB TRAMETINIB IPILIMUMAB PEMBROLIZUMAB NIVOLUMAB Austria Belgium ** ** Denmark France Germany Greece ** ** Italy Netherlands Portugal ** ** ** ** ** ** ** Spain *** *** Sweden Switzerland ** UK Albania Belarus Bosnia and Herzegovina Bulgaria Croatia Czech republic * * ** ** Estonia Hungary ** ** ** ** ** Lithuania Macedonia Montenegro ** Poland * * ** ** Romania Russia *** **** **** ** Serbia Slovenia Ukraine Registered Reimbursed Not registered Not reimbursed Switzerland: T-Vec registration and reimbursement
27
28 ESMO-MCBS could be used as a policy tool in HTA and reimbursement decisions at the national level?
29 29
30 Presented By Elisabeth De Vries at 2017 ASCO Annual Meeting 30
31 WHO Essential antineoplastic medicines
32 Added: nilotinib and dasatinib for imatinib resistant CML Establishment of EML cancer medicines working group to coordinate comprehensive evaluation of cancer medicines for the EML Cooperation between ESMO and WHO: possible implementation of ESMO-MCBS in evaluation of medicines for the WHO essential list? 32
33 Non-curative setting: 1 st line Medication Trial name First author Early crossover Primary outcome PFS control (months) PFS gain (months) PFS HR OS control (months) OS gain (months) OS HR Increase in 2-year OS 10% QoL Toxicity ESMO MCBS v1.1 non-curative DABRAFENIB TRAMETINIB COMBI-D Long G 2015, 2017 no PFS YES + 4 VEMURAFENIB Ascierto P COBRIM 2016 COBIMETINIB no PFS YES + 4 IPILIMUMAB Maio 2015 Maio 2015 yes OS YES 4 NIVOLUMAB PEMBROLIZUMAB NIVOLUMAB + IPILIMUMAB CHECKMATE 066 KEYNOTE-006 CHECKMATE 067 Robert 2015 Atkinson SMR 2015 no OS NR 0.43 YES + 4 Robert 2015 Schachter ASCO 2016 yes OS YES 4 Larkin 2015 Larkin AACR 2017 Scadendorf 2017 no OS NR NR ND ND same + 3 NIVOLUMAB + IPILIMUMAB PDL1 CHECKMATE 067 Larkin 2015 Larkin AACR 2017 no OS NR NR ND ND 4 33
34 Curative setting Medication Trial name First author Early crossover Primary outcome PFS control (months) PFS gain (months) PFS HR OS control (months) OS gain (months) OS HR Increase in 2-year OS 10% >5% imp. of survival at 3 year FU QoL Toxicity ESMO MCBS v1.1 curative ESMO MCBS v1.1 non-curative DABRAFENIB TRAMETINIB COMBI-D Long G 2015, 2017 no PFS YES YES + A 4 VEMURAFENIB COBIMETINIB COBRIM Ascierto P 2016 IPILIMUMAB Maio 2015 Maio 2015 NIVOLUMAB CHECKMATE 066 Robert 2015 Atkinson no PFS YES NA + ND 4 yes OS YES YES A 4 SMR 2015 no OS NR 0.43 YES YES + A 4 PEMBROLIZUMAB NIVOLUMAB + IPILIMUMAB KEYNOTE-006 CHECKMATE 067 Robert 2015 Schachter ASCO 2016 Larkin 2015 Larkin AACR 2017 yes OS YES YES A 4 no OS NR NR ND ND NA same + ND 3 NIVOLUMAB + IPILIMUMAB PDL1+ CHECKMATE 067 Larkin 2015 Larkin AACR 2017 no OS NR NR ND ND NA ND 4 34
35 Adjuvant interferon-alpha meta analysis Ives NJ et al. Eur J Cancer 2017; 82: OS improvement 3% at 5 years (HR 0.9, CI ), grade B Subgroup analysis: Ulcerated tumors OS improvement 10.5% at 10 years (HR 0.77, CI ), grade A Adjuvant ipilimumab, EORTC OS improvement 11% at 5 years (HR 0.72), grade A Substantial toxicity, QoL not deteriorated, downgrade to B? ESMO 2017: Dabrafenib+trametinib? Vemurafenib? Pembrolizumab? 35
36 Percentage of countries (%) Vemurafenib Dabrafenib Vemurafenib cobimetinib registration Dabrafenib trametinib Ipilimumab Pembrolizumab Nivolumab Nivolumab ipilimumab ESMO MCBS (5) 4 (5) 4 4 (5) 4 (5) 3 (4) reimbursement 36
37
38 o o o EU Directive recommendation that registered medicine should be available on the market in 120 days, but delays are common EU Network for Health Technology Assessment: o Harmonization of cost-effectiveness analysis until 2020 o Parallel submissions to EMA and EU HTA proposed o Common EU price? o ESMO-MCBS as a tool for centralized prioritization? Harmonization of reimbursement process? o Added value reimbursement prioritization based on the central assessment of added value for each medicine OR assessment of added value at the national level
39 Pricing?
40 National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in in South Korea. Kim ES, et al. Expert Rev Pharmacoecon Outcomes Res Jan 3:1-9. Three variables increased the likelihood of reimbursement listing: clinical improvement, below alternative s price, risk-sharing arrangement. Cancer drug s listing increased from 17% to 47% after risk-sharing agreement implementation.
41
42 Take an active role through involvement in professional oncological organizations to start and maintain a dialogue with: European and national policy makers Patients organizations Pharmaceutical industry to improve the access to innovative medicines for their patients. Education of practicing oncologists is necessary to ensure basic understanding of the process of drug approval and reimbursement in order to be able to actively participate in the process.
43 43
44 A dynamic tool with planned revisions and updates based on careful and transparent revision process Commitment to accountability for reasonableness Could serve as useful tool for establishing a fair process for priority setting in public policy Further adjustments: patient reported outcomes 44
45 EU Policy Committee, Global Policy Committee Working Group for the access to medicines Task Force for innovation in skin cancer care Thank you for your attention!
WCPT COUNTRY PROFILE December 2017 SWEDEN
WCPT COUNTRY PROFILE December 2017 SWEDEN SWEDEN NUMBERS WCPT Members Practising physical therapists 11,043 Total number of physical therapist members in your member organisation 17,906 Total number of
More informationWCPT COUNTRY PROFILE December 2017 HUNGARY
WCPT COUNTRY PROFILE December 2017 HUNGARY HUNGARY NUMBERS WCPT Members Practising physical therapists 727 Total number of physical therapist members in your member organisation 4,000 Total number of practising
More informationWCPT COUNTRY PROFILE December 2017 SERBIA
WCPT COUNTRY PROFILE December 2017 SERBIA SERBIA NUMBERS WCPT Members Practising physical therapists 622 Total number of physical therapist members in your member organisation 3,323 Total number of practising
More informationWhere we stand in EFORT
Where we stand in EFORT Engaging with the new EU regulatory landscape for medical devices. Challenges & opportunities Brussel, Belgium April 6, 2018 Per Kjaersgaard-Andersen Associate Professor Section
More informationAlcohol-related harm in Europe and the WHO policy response
Alcohol-related harm in Europe and the WHO policy response Lars Moller Programme Manager World Health Organization Regional Office for Europe Date of presentation NCD global monitoring framework: alcohol-related
More informationQ1 What age are you?
Q1 What age are you? Answered: 504 Skipped: 0 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 4.56% 23 3.77% 19 4.56% 23 6.15% 31 3.97% 20 6.55% 33 5.95% 30 6.75% 34 6.35% 32 4.37% 22 6.75% 34 5.56%
More informationSmokefree Policies in Europe: Are we there yet?
Smokefree Policies in Europe: Are we there yet? 14 April 2015, 9:00 10:30am Rue de l Industrie 24, 1040 Brussels Permanent Partners: Temporary Partners: The research for the SFP Smokefree Map was partially
More informationMedia Release. Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences
Media Release Embargoed 00.01 CET Monday 12 th March 2012 Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences Up to 70 percent of
More informationLEBANON. WCPT COUNTRY PROFILE December 2018
LEBANON WCPT COUNTRY PROFILE December 2018 LEBANON NUMBERS 1600 1400 1200 1000 800 600 400 200 0 Physical therapists in the country Members in MO 1,480 1,480 Total PTs in country 800000 700000 600000 500000
More informationDENMARK. WCPT COUNTRY PROFILE December 2018
DENMARK WCPT COUNTRY PROFILE December 2018 DENMARK NUMBERS 14000 12000 10000 8000 6000 4000 2000 0 Physical therapists in the country Members in MO 11,720 12,975 Total PTs in country 800000 700000 600000
More informationEuropean status report on alcohol and health Leadership, awareness and commitment
European status report on alcohol and health 2014 Leadership, awareness and commitment Leadership, awareness and commitment Background Strong leadership from national and local governments is essential
More informationGERMANY. WCPT COUNTRY PROFILE December 2018
GERMANY WCPT COUNTRY PROFILE December 2018 GERMANY NUMBERS 160000 140000 120000 100000 80000 60000 40000 20000 0 Physical therapists in the country Members in MO 21,502 136,000 Total PTs in country 800000
More informationEuropean Status report on Alcohol and Health
European Status report on Alcohol and Health Dr Lars Moller Regional Advisor a.i. WHO Regional Office for Europe Main killers in the WHO European Region Source: Preventing chronic diseases. A vital investment.
More informationInequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe
Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe 21st Congress of the European Association of Dental Public Health 1 October 2016 Budapest
More informationEngagement in language assessment / Regions of Europe
Summary table: Engagement in language / Regions of This table lists the statistically significant differences in the engagement in activities by the respondents from different s of : If the word or appears
More informationPrevention of Oral Cancer Special Interest Working Group
Prevention of Oral Cancer Special Interest Working Group Dr Colwyn Jones, Consultant in Dental Public Health, NHS Health Scotland, 1 South Gyle Crescent, Edinburgh EH12 9EB, Scotland. colwyn.jones@nhs.net
More informationEuropean Association of Dental Public Health Prevention of Oral Cancer
European Association of Dental Public Health Prevention of Oral Cancer Special Interest Working Group Thursday 14th November 2013 PD Dr. Katrin Hertrampf, MPH Dr. Colwyn Jones, Associate Editor Malta 2013
More informationWHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA
WHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA September 2017 Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for Europe Marmorvej
More informationPARALLELISM AND THE LEGITIMACY GAP 1. Appendix A. Country Information
PARALLELISM AND THE LEGITIMACY GAP 1 Appendix A Country Information PARALLELISM AND THE LEGITIMACY GAP 2 Table A.1 Sample size by country 2006 2008 2010 Austria 2405 2255 0 Belgium 1798 1760 1704 Bulgaria
More informationRECOMMENDATIONS ON INFLUENZA VACCINATION DURING THE WINTER SEASON
RECOMMENDATIONS ON INFLUENZA VACCINATION DURING THE 2018 2019 WINTER SEASON October 2018 Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for
More informationA report on the epidemiology of selected vaccine-preventable diseases in the European Region 30% 20% 10%
% of reported measles cases WHO EpiBrief A report on the epidemiology of selected vaccine-preventable diseases in the European Region No. /17 This issue of WHO EpiBrief provides an overview of selected
More informationThe cancer burden in the European Union and the European Region: the current situation and a way forward
The cancer burden in the European Union and the European Region: the current situation and a way forward Presented by Zsuzsanna Jakab WHO Regional Director for Europe Informal Meeting of Health Ministers
More informationEuropean Collaboration on Dementia. Luxembourg, 13 December 2006
European Collaboration on Dementia Luxembourg, 13 December 2006 2005 Call for projects Special attention has also to be given to information and definition of indicators on neurodegenerative, neurodevelopment,
More informationHighlighting in the WHO European Region: Summary. No. 21(February 2012)
No. 21(February 2012) Issue 15, April 2011 A monthly publication on vaccine preventable diseases and immunization data and analysis Highlighting in the WHO European Region: Update on measles in the European
More informationCross Border Genetic Testing for Rare Diseases
Cross Border Genetic Testing for Rare Diseases EUCERD Joint Action WP8 Helena Kääriäinen National Institute for Health an Welfare, Helsinki, Finland Starting point Possibilities and demand for genetic
More informationNational Institute on Alcohol Abuse and Alcoholism. Environmental Approaches
Environmental Approaches Consumption of 10+ and 21+ Drinks on an Occasion At Least Once in the Past Year, 2013 30 25 20 15 10+ drinks 15 25 10+ drinks 16 25 10 5 0 21+ drinks 3 2 21+ drinks 18-20 21-24
More informationTable 9.1 Summary information for stomach cancer in Ireland,
9 Stomach cancer 9.1 Summary Stomach cancer ranks seventh in terms of the most common cancers in Ireland, accounting for 4.1% of all malignant neoplasia in men and 2.8% in women, when non-melanoma skin
More informationDepartment of Biological Standardisation OMCL Network & Healthcare (DBO)
Department of Biological Standardisation OMCL Network & Healthcare (DBO) Implementation of Pathogen Reduction Technologies for Blood Components for Transfusion: Updated Table 2009-2010 COUNCIL OF EUROPE
More informationAccess to treatment and disease burden
Access to treatment and disease burden Robert Flisiak Department of Infectious Diseases and Hepatology Medical University in Białystok, Poland Moulin de Vernègues, 27-29 August 2015 Disclosures Advisor
More informationHighlighting in the WHO European Region: measles outbreaks rubella surveillance acute flaccid paralysis surveillance
No. 17 (September 2011) A monthly publication on vaccine preventable diseases and immunization data and analysis Issue 15, April 2011 Highlighting in the WHO European Region: measles outbreaks rubella
More informationHighlighting in the WHO European Region:
No. 23(April 2012) Issue 15, April 2011 A monthly publication on vaccine preventable diseases and immunization data and analysis Highlighting in the WHO European Region: Update on measles in the European
More informationBurden and cost of alcohol, tobacco and illegal drugs globally and in Europe
Burden and cost of alcohol, tobacco and illegal drugs globally and in Europe Jürgen Rehm 1-4 Kevin D. Shield 1,2,3 1) Centre for Addiction and Mental Health, Toronto, Canada 2) University of Toronto, Canada
More informationOverview of drug-induced deaths in Europe - What does the data tell us?
Overview of drug-induced deaths in Europe - What does the data tell us? João Matias, Isabelle Giraudon, Julián Vicente EMCDDA expert group on the key-indicator Drug-related deaths and mortality among drug
More informationBiology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?
Biology Report Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis? Introduction Tuberculosis is a serious disease caused by the bacterium Mycobacterium
More informationTable 7.1 Summary information for lung cancer in Ireland,
7 Lung cancer 7.1 Summary Lung cancer is the third most common cancer in Ireland, accounting for 15% of cancers in men and 9% in women, if non-melanoma skin cancer is excluded (table 7.1). Each year, approximately
More informationBest practices in collecting and processing data in CRC screening and after it
Best practices in collecting and processing data in CRC screening and after it The potential of harmonized information policy in effective national implementation of CRC screening Ladislav Dušek, Czech
More informationEURO POLIO PAGE Data as of 04 October 2005 (Week 38)
World Health Organization Regional Office for Europe EURO POLIO PAGE Data as of 04 October 2005 (Week 38) Vaccine-preventable Diseases and Immunization programme, Division of Technical Support website:
More informationEUDY JUNIOR CAMP 2018 FIRST ANNOUNCEMENT
EUDY JUNIOR CP 2018 FIRST ANNOUNCEMENT 21. 29. July 2018 Tesáre, SLOVAKIA IDENTITY OF THE DEAF EUROPEAN UNION OF THE DEAF YOUTH (EUDY) The European Union of the Deaf Youth is a European non-profit organisation
More informationTable 6.1 Summary information for colorectal cancer in Ireland,
6 Colorectal cancer 6.1 Summary Colorectal cancer is the second most common cancer in Ireland (excluding non-melanoma skin cancer). It accounts for 12% of all malignant neoplasia in females and 15% in
More informationMEDICINES SHORTAGES PGEU GPUE. John Chave - Secretary general. Pharmaceutical Group of European Union Groupement Pharmaceutique de l Union Européenne
MEDICINES SHORTAGES John Chave - Secretary general Members: Professional Bodies & Pharmacists Associations 2013: 32 Countries Austria Belgium Bulgaria Bosnia Herzegovina Cyprus Czech Rep Denmark Estonia
More information11 Melanoma of the skin
11 Melanoma of the skin 11.1 Summary Melanoma of the skin is the ninth most common cancer in Ireland, accounting for 2.4 of all malignant neoplasia in men and 4.2 in women, if non-melanoma skin cancers
More informationThe Current Status of Cardiac Electrophysiology in ESC Member Countries J. Brugada, P. Vardas, C. Wolpert
Albania. Algeria. Armenia. Austria. Belarus. Belgium. Bosnia & Herzegovina. Bulgaria. Croatia. Cyprus. Czech Republic Denmark. Egypt. Estonia. Finland. Former Yugoslav Republic of Macedonia. France. Georgia.
More informationCALL FOR A EUROPEAN ACTION PLAN FOR MEDICAL IMAGING TO IMPROVE QUALITY OF CARE AND PATIENT SAFETY
CALL FOR A EUROPEAN ACTION PLAN FOR MEDICAL IMAGING TO IMPROVE QUALITY OF CARE AND PATIENT SAFETY myesr.org QUALITY & SAFETY Improving and harmonising quality and safety in medical imaging across Europe
More informationManuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal
Manuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal Public Health Public health is the science and art of preventing disease, prolonging
More informationSummary. Primary care data. Week 49/2014. Season
Summary Week 49/2014 In week 49/2014, influenza activity remained low across the WHO European Region. Twenty countries reported sporadic influenza activity and nine reported increasing trends in consultations
More informationALCOHOL CONSUMPTION IN EUROPE; TRADITIONS, GENERATIONS, CULTURE AND POLICY
ALCOHOL CONSUMPTION IN EUROPE; TRADITIONS, GENERATIONS, CULTURE AND POLICY JACEK MOSKALEWICZ INSTITUTE OF PSCHIATRY AND NEUROLOGY WARSAW, POLAND THIRD EUROPEAN CONFERENCE ON ALCOHOL AND LAW ENFORCEMENT,
More informationThe health economic landscape of cancer in Europe
1 Approval number The health economic landscape of cancer in Europe Bengt Jönsson, Professor Emeritus of Health Economics Stockholm School of Economics 2 Disclaimer This presentation was developed by Professor
More informationAnimal health situation of OIE Member Countries in Europe 1 st semester 2012 (and previous)
Animal health situation of OIE Member Countries in Europe 1 st semester 2012 (and previous) 25 th Conference of the OIE Regional Commission for Europe 17 th to 21 st September 2012, Fleesensee Germany
More informationDevelopment of Palliative Care services in different countries
Development of Palliative Care services in different countries Nicoleta Mitrea EONS leadership summit, 2017 Disclosure speaker Do you have any interest to declare? No, I don t have any interest to declare.
More informationRheumatoid Arthritis Disease Burden and Access to Treatment
Berlin, April 2012 Rheumatoid Arthritis Disease Burden and Access to Treatment Gisela Kobelt, PhD Visiting Professor, Lund University (Sweden) President, European Health Economics (France) Disclaimers
More informationMeasles and rubella monitoring January 2015
Measles and rubella monitoring January 215 Reporting on January December 214 surveillance data and epidemic intelligence data to the end of January 215 Main developments Measles During the 12-month period
More informationCancer drug costs and payment issues in European countries.
Cancer drug costs and payment issues in European countries. Wim van Harten MD PhD, Riin Ots, Valesca Retel PhD, Anke Wind MSc. ECPC June 2017 Affiliations: The Netherlands Cancer Institute; University
More informationResearch paper: Legal treatment of the use of cannabis for medical purposes in the member states of the European Union
Parliament of Montenegro Parliamentary Institute Research Centre Research paper: Legal treatment of the use of cannabis for medical purposes in the member states of the European Union Podgorica, December
More informationHPV vaccination How to promote women s health and prevent cancer with good screening strategies, hosted by NFOG
HPV vaccination How to promote women s health and prevent cancer with good screening strategies, hosted by NFOG Pekka Nieminen MD, PhD and Miriam Elfström, PhD Chief Physician, Associate Professor Dept.Obstetrics
More informationMonthly measles and rubella monitoring report
SURVEILLANCE REPORT Monthly measles and rubella monitoring report December 2018 Period covered: 1 November 2017 to 31 October 2018 Introduction This monitoring report is based on measles and rubella data
More informationEUDY CHILDREN CAMP 2017 FIRST ANNONUCEMENT
EUDY CHILDREN CP 2017 FIRST ANNONUCEMENT 08 15 July 2017 Prašník Dúbrava, SLOVAKIA THE IDENTITY OF A YOUNG DEAF CHILD EUROPEAN UNION OF THE DEAF YOUTH (EUDY) The European Union of the Deaf Youth is a European
More informationSituation update in the European Region: overview of influenza surveillance data week 40/2009 to week 07/2010.
Situation update in the European Region: overview of influenza surveillance data week 40/2009 to week 07/2010. WHO/Europe publishes a weekly electronic bulletin on influenza activity in the Region 1 and
More informationFinnish international trade 2017 Figures and diagrams. Finnish Customs Statistics
Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11
More informationDrinking guidelines used in the context of early identification and brief interventions in Europe: overview of RARHA survey results
Drinking guidelines used in the context of early identification and brief interventions in Europe: overview of RARHA survey results E. Scafato, C. Gandin, L. Galluzzo, S. Ghirini, S. Martire Istituto Superiore
More informationFinnish international trade 2017 Figures and diagrams. Finnish Customs Statistics
Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11
More informationIs there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?
Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis? Introduction Tuberculosis is a serious disease caused by the bacterium Mycobacterium tuberculosis.
More informationNoncommunicable diseases progress monitoring. Are we meeting the time-bound United Nations targets?
Noncommunicable diseases progress monitoring Are we meeting the time-bound United Nations targets? Background paper for the WHO European Meeting of National NCD Directors and Programme Managers, Moscow,
More informationPatients Perspective on TKI Generics in Haematology
Patients Perspective on TKI Generics in Haematology Šarūnas Narbutas President, POLA Milan, 14 June 2014 Outlook: TKI* Generics in the EU Market FIRST PATENT EXPIRATION EXCLUSIVITY EXPIRATION (EMA) INN
More informationTEDDY. Teddy Network of Excellence. Annagrazia ALTAVILLA. Ph.D. Sciences Ethics LL.M. Health Law. diterranée
Teddy Network of Excellence Annagrazia ALTAVILLA TEDDY Task-force in Europe for Drug Development for the Young Ph.D. Sciences Ethics LL.M. Health Law Associated Senior Lecturer Université de la MéditerranM
More informationEU Market Situation for Poultry. Committee for the Common Organisation of the Agricultural Markets 20 April 2017
EU Market Situation for Poultry Committee for the Common Organisation of the Agricultural Markets 2 April 217 -9.% -11.% -5.% -.1% -.7% -2.2% 3.% 1.7% 1.2%.8%.6%.%.%.% 7.9% 7.% 6.4% 6.2% 6.% 5.5% 5.3%
More informationWorld Health Organization Regional Office for Europe Surveillance of measles and rubella Data as of 15 March 2006
World Health Organization Regional Office for Europe Surveillance of measles and rubella Data as of 15 March 2006 WHO Regional Office for Europe Vaccine-preventable Diseases and Immunization programme,
More informationUK bowel cancer care outcomes: A comparison with Europe
UK bowel cancer care outcomes: A comparison with Europe What is bowel cancer? Bowel cancer, which is also known as colorectal or colon cancer, is a cancer that affects either the colon or the rectum. The
More informationWhere do EU Contries set the limit for low risk drinking.
Where do EU Contries set the limit for low risk drinking. Results from the EU RARHA survey E. Scafato,L. Galluzzo, S. Ghirini, C. Gandin Istituto Superiore di Sanità, Italy WP5: Outline of the work (tasks)
More informationUnderage drinking in Europe
Underage drinking in Europe There are two major studies on underage drinking which are published every 4 years: HBSC (Health Behaviour in School-aged Children) and ESPAD (The European School survey Project
More informationHPAI H5(N8) in Member States in poultry, captive and wild birds
HPAI H5(N8) in Member States in poultry, captive and wild birds (01/10/2016-01/03/2017) DG Health and Food Safety 13,578,000 5,610,000 234,000 Broad migration flows of ducks across Europe 1,000,000 71,000
More informationIOSH No Time to Lose campaign: working together to tackle asbestos-related cancer #NTTLasbestos. Jonathan Hughes IOSH Vice President
IOSH No Time to Lose campaign: working together to tackle asbestos-related cancer #NTTLasbestos Jonathan Hughes IOSH Vice President About the Institution of Occupational Safety and Health (IOSH) www.iosh.co.uk
More informationPRESS RELEASE ISSUED BY THE STATE UNIVERSITY OF NEW YORK AT ALBANY
PRESS RELEASE ISSUED BY THE STATE UNIVERSITY OF NEW YORK AT ALBANY EMBARGOED FOR RELEASE AT 6:00A.M. EST, FEBRUARY 20, 2001. NOTE TO EDITORS These results will be presented today (Tuesday, February 20,
More informationThe EHRA White Book 2009 The Current Status of Cardiac Electrophysiology in ESC Member Countries J. Brugada, P. Vardas, C. Wolpert
Albania. Algeria. Armenia. Austria. Belarus. Belgium. Bosnia & Herzegovina. Bulgaria. Croatia. Cyprus. Czech Republic Denmark. Egypt. Estonia. Finland. Former Yugoslav Republic of Macedonia. France. Georgia.
More informationREPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS
EUROPEAN COMMISSION Brussels, 17.6.011 COM(011) 35 final REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS
More informationEmerging Risks Mapping of Activities in Member States. 67th Advisory Forum meeting, Utrecht, The Netherlands, 6 February 2018
Emerging Risks Mapping of Activities in Member States 67th Advisory Forum meeting, Utrecht, The Netherlands, 6 February 2018 BACKGROUND 67 th Advisory Forum Meeting, Utrecht, The Netherlands, 6 February
More informationReal Life, Real PD Survey
Real Life, Real PD Survey Final Pan-European Survey Results Survey Objectives The survey was carried out to provide insights into the realities of living with PD and to highlight some of the symptoms of
More informationCannabis policies & cannabis use
Cannabis policies & cannabis use Point of departure Does an increased interest in cannabis regulation result in the tendency to view the world through a lens that gives an over emphasis to, or over simplifies,
More informationEuropean Community Pharmacy: a reference in Public Health
European Community Pharmacy: a reference in Public Health Ilaria Passarani PGEU Secretary General 4 October 2018, Burgos, Spain Pharmaceutical Group of European Union Members: Professional Bodies & Pharmacists
More informationThe Identification of Food Safety Priorities using the Delphi Technique
The Identification of Food Safety Priorities using the Delphi Technique Gene Rowe & Fergus Bolger, GRE 58th Advisory Forum Meeting, Luxembourg, 8-9 December 2015 EU RISK ASSESSMENT AGENDA (RAA) where priorities
More informationAnalysis of 3-dose oral/inactivated poliovirus vaccine (OPV3/IPV3) immunization coverage
A MONTHLY NEWSLETTER OF THE COMMUNICABLE DISEASE UNIT, WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR EUROPE, COPENHAGEN, DENMARK Issue 5, March 2009 Analysis of 3-dose oral/inactivated poliovirus vaccine
More informationReflecting on ten years of progress in the fight against AIDS, TB and malaria
Reflecting on ten years of progress in the fight against AIDS, TB and malaria Michel Kazatchkine UN Secretary General s Special Envoy on HIV/AIDS in Eastern Europe and central Asia Ten years of progress:
More informationVaccinations pre- and posttransplant. Burkhard Tönshoff, MD, PhD University Children s Hospital Heidelberg, Germany
Vaccinations pre- and posttransplant Burkhard Tönshoff, MD, PhD University Children s Hospital Heidelberg, Germany Background Increased risk of both common and opportunistic infections after Tx due to
More informationREVIEW OF THE ANALYSIS RELATED TO RABIES DIAGNOSIS AND FOLLOW-UP OF ORAL VACCINATION PERFORMED IN NRLS IN 2015
European Union European Union WHO Collaborating OIE Reference Reference Centre Reference NANCY LABORATORY FOR RABIES AND WILDLIFE Laboratory for Rabies Institute for Rabies Serology for Research and Management
More informationYersiniosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods. Epidemiology
SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Yersiniosis Key facts In 2015, 26 countries reported 7 279 confirmed yersiniosis cases in the EU/EEA. The overall notification rate was 2.0 cases
More informationGERIATRIC TEACHING AND TRAINING IN EUROPE: Where are we? (part I)
GERIATRIC TEACHING AND TRAINING IN EUROPE: Where are we? (part I) Pr. Olivier Beauchet, MD, PhD Department of Neuroscience Geriatrics Division and Memory Clinic Angers University Hospital and School of
More information15 yers of Czech National Breast Cancer Screening Programme
15 yers of Czech National Breast Cancer Screening Programme Miroslava Skovajsová, Jan Daneš, Helena Bartoňková Ondřej Májek, Ondřej Ngo, Daniel Klimeš, Ladislav Dušek Breast cancer screening and national
More informationPalliative nursing care of children and young people across Europe
Palliative nursing care of children and young people across Europe Results of a postal survey in August 2016 Updated in April 2017 (presented at the 29th PNAE-meeting in Naples/Italy on 28th April 2017)
More informationInequality in injury risks
Inequality in injury risks Rationale Injuries a are a neglected but preventable epidemic and in the 53 countries in the WHO European Region account for nearly 800 000 lives lost annually (equivalent to
More informationTrichinellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods
Annual Epidemiological Report for 2015 Trichinellosis Key facts In 2015, a total of 156 confirmed cases of trichinellosis was reported from 29 EU/EEA countries. The overall notification rate was 0.03 cases
More informationMen & Health Work. Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013
Men & Health Promotion @ Work Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013 Difference can make a Difference Mens health: State of mens health Use of services Role of the
More informationCND UNGASS FOLLOW UP
CND UNGASS FOLLOW UP INCB follow-up activities on Chapter 2. Operational recommendations on ensuring the availability of and access to controlled substances exclusively for medical and scientific purposes,
More informationEHFG 2016 Sustainable and equitable cancer care: tomorrow s reality or science-fiction?
1 Approval number EHFG 2016 Sustainable and equitable cancer care: tomorrow s reality or science-fiction? 28 th September 2016 The Oncologist s perspective What can and should be changed in order to optimise
More informationNutrient profiles for foods bearing claims
Nutrient profiles for foods bearing claims Fields marked with * are mandatory. Background Regulation (EC) 1924/2006 (Nutrition and Health Claims NHC Regulation) establishes EU rules on nutrition and health
More information